[{"id":"842583e2-8e92-49fc-94d6-2f73865d1b14","acronym":"","url":"https://clinicaltrials.gov/study/NCT07203352","created_at":"2025-10-04T08:00:11.817Z","updated_at":"2025-10-04T08:00:11.817Z","phase":"Phase 3","brief_title":"Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL","source_id_and_acronym":"NCT07203352","lead_sponsor":"Nanfang Hospital, Southern Medical University","biomarkers":" ABL2","pipe":"","alterations":" ","tags":["ABL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 10/01/2025","start_date":" 10/01/2025","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-10-02"},{"id":"a8dbbb89-8bb1-4f12-ad96-eb67e83dce09","acronym":"","url":"https://clinicaltrials.gov/study/NCT00265798","created_at":"2021-01-18T00:54:12.869Z","updated_at":"2025-02-25T13:47:55.628Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate","source_id_and_acronym":"NCT00265798","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KIT","pipe":" | ","alterations":" KIT expression","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • imatinib • sunitinib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 09/14/2005","start_date":" 09/14/2005","primary_txt":" Primary completion: 02/11/2010","primary_completion_date":" 02/11/2010","study_txt":" Completion: 03/08/2025","study_completion_date":" 03/08/2025","last_update_posted":"2025-02-20"},{"id":"6858793b-66b6-4bd1-8de9-e5db913af128","acronym":"","url":"https://clinicaltrials.gov/study/NCT03533582","created_at":"2021-01-18T17:24:25.522Z","updated_at":"2025-02-25T15:10:48.947Z","phase":"Phase 3","brief_title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","source_id_and_acronym":"NCT03533582","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCB1 • AFP","pipe":" | ","alterations":" AFP elevation","tags":["SMARCB1 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 05/24/2018","start_date":" 05/24/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"},{"id":"6b3ddb38-36c4-4cd2-88af-350ae7a6b2ce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05468359","created_at":"2022-07-21T11:55:04.366Z","updated_at":"2025-02-25T16:54:21.817Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients","source_id_and_acronym":"NCT05468359","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • sorafenib • cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 11/07/2022","start_date":" 11/07/2022","primary_txt":" Primary completion: 06/01/2032","primary_completion_date":" 06/01/2032","study_txt":" Completion: 06/01/2037","study_completion_date":" 06/01/2037","last_update_posted":"2025-02-04"},{"id":"de01f4b4-b380-45e4-a05f-0573156a9b1c","acronym":"AAML1031","url":"https://clinicaltrials.gov/study/NCT01371981","created_at":"2021-01-18T05:37:13.447Z","updated_at":"2025-02-25T16:51:07.072Z","phase":"Phase 3","brief_title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT01371981 - AAML1031","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1645","initiation":"Initiation: 06/20/2011","start_date":" 06/20/2011","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-04"},{"id":"2cfcde7a-d491-42b2-9d06-8123de42c77d","acronym":"A091302","url":"https://clinicaltrials.gov/study/NCT02143726","created_at":"2021-09-08T20:53:26.218Z","updated_at":"2025-02-25T15:41:37.517Z","phase":"Phase 2","brief_title":"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer","source_id_and_acronym":"NCT02143726 - A091302","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" TG","pipe":"","alterations":" ","tags":["TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 10/09/2014","start_date":" 10/09/2014","primary_txt":" Primary completion: 01/28/2021","primary_completion_date":" 01/28/2021","study_txt":" Completion: 08/06/2028","study_completion_date":" 08/06/2028","last_update_posted":"2025-01-27"},{"id":"e654c874-ff26-4818-92d4-ab360c653d3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068752","created_at":"2021-10-06T12:53:53.320Z","updated_at":"2025-02-25T17:25:17.327Z","phase":"Phase 2","brief_title":"Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer","source_id_and_acronym":"NCT05068752","lead_sponsor":"HonorHealth Research Institute","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • sorafenib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2021","start_date":" 10/28/2021","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-09-19"},{"id":"da630ed2-aba8-4d08-84f9-a31e25b0efa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06527495","created_at":"2025-02-27T07:56:52.092Z","updated_at":"2025-02-27T07:56:52.092Z","phase":"Phase 1/2","brief_title":"Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma","source_id_and_acronym":"NCT06527495","lead_sponsor":"Assiut University","biomarkers":" KDR • VEGFA","pipe":"","alterations":" ","tags":["KDR • VEGFA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-07-30"},{"id":"8a480ed5-36f4-4c94-a8ca-7de2924f7398","acronym":"","url":"https://clinicaltrials.gov/study/NCT03211416","created_at":"2021-01-18T15:50:22.610Z","updated_at":"2025-02-25T16:06:31.337Z","phase":"Phase 1/2","brief_title":"Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer","source_id_and_acronym":"NCT03211416","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1 • PD-L2","pipe":"","alterations":" ","tags":["PD-L1 • PD-L2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sorafenib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 12/07/2024","study_completion_date":" 12/07/2024","last_update_posted":"2024-07-03"},{"id":"ba1ff799-4c96-4b36-abc9-9696cce6175e","acronym":"NCI-2018-01836","url":"https://clinicaltrials.gov/study/NCT00494182","created_at":"2021-01-18T01:46:04.063Z","updated_at":"2024-07-02T16:35:01.215Z","phase":"Phase 2","brief_title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","source_id_and_acronym":"NCT00494182 - NCI-2018-01836","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1","pipe":" | ","alterations":" TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression","tags":["HER-2 • TP53 • HIF1A • CD34 • EPAS1 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • HER-2 expression • TP53 expression • CD31 expression • HIF1A expression • CA9 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • sorafenib • paclitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/25/2007","start_date":" 04/25/2007","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-24"},{"id":"0ddf2dab-b38d-4054-a616-48669cd75157","acronym":"","url":"https://clinicaltrials.gov/study/NCT02143401","created_at":"2021-01-18T09:57:19.810Z","updated_at":"2024-07-02T16:35:01.909Z","phase":"Phase 1","brief_title":"Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors","source_id_and_acronym":"NCT02143401","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MCL1 • AFP • CASP3","pipe":" | ","alterations":" MCL1 expression","tags":["MCL1 • AFP • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • navitoclax (ABT 263)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 11/07/2014","start_date":" 11/07/2014","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 05/20/2025","study_completion_date":" 05/20/2025","last_update_posted":"2024-05-22"},{"id":"25179c5b-c443-4dc5-8695-a99257e723d2","acronym":"PEDS-PLAN","url":"https://clinicaltrials.gov/study/NCT02559778","created_at":"2021-01-18T12:23:35.740Z","updated_at":"2024-07-02T16:35:10.996Z","phase":"Phase 2","brief_title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","source_id_and_acronym":"NCT02559778 - PEDS-PLAN","lead_sponsor":"Giselle Sholler","biomarkers":" MYCN","pipe":" | ","alterations":" MYCN amplification","tags":["MYCN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYCN amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • sorafenib • Zykadia (ceritinib) • Zolinza (vorinostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 500","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/01/2030","primary_completion_date":" 09/01/2030","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-04-08"},{"id":"f374dc4d-c613-437c-8a29-943b1442e3ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT01303341","created_at":"2021-01-18T05:18:01.764Z","updated_at":"2024-07-02T16:35:13.428Z","phase":"Phase 1","brief_title":"Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma","source_id_and_acronym":"NCT01303341","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":" | ","alterations":" BCL2 expression • MCL1 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL2 expression • MCL1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • riluzole"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 02/18/2011","start_date":" 02/18/2011","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 09/09/2024","study_completion_date":" 09/09/2024","last_update_posted":"2024-03-21"},{"id":"58b304d1-88f8-40d0-bb45-35856fffc559","acronym":"","url":"https://clinicaltrials.gov/study/NCT06030895","created_at":"2023-09-11T16:10:25.154Z","updated_at":"2024-07-02T16:35:15.169Z","phase":"","brief_title":"Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.","source_id_and_acronym":"NCT06030895","lead_sponsor":"Damanhour University","biomarkers":" IL6","pipe":"","alterations":" ","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 12/12/2022","start_date":" 12/12/2022","primary_txt":" Primary completion: 02/21/2024","primary_completion_date":" 02/21/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2024-03-12"},{"id":"61330035-2bc7-439b-bba8-448926a17e6f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00096434","created_at":"2021-01-18T00:18:05.214Z","updated_at":"2024-07-02T16:35:15.818Z","phase":"Phase 2","brief_title":"Sorafenib in Treating Patients With Metastatic Breast Cancer","source_id_and_acronym":"NCT00096434","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 09/01/2004","start_date":" 09/01/2004","primary_txt":" Primary completion: 06/01/2006","primary_completion_date":" 06/01/2006","study_txt":"","study_completion_date":"","last_update_posted":"2024-03-07"},{"id":"47481f7c-4d73-4ee0-9312-6b63c4d1442d","acronym":"BCTOP-L-M05","url":"https://clinicaltrials.gov/study/NCT05594095","created_at":"2022-10-26T13:56:12.698Z","updated_at":"2024-07-02T16:35:20.799Z","phase":"Phase 2","brief_title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","source_id_and_acronym":"NCT05594095 - BCTOP-L-M05","lead_sponsor":"Fudan University","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 amplification • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • albumin-bound paclitaxel • fulvestrant • exemestane • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-02-06"},{"id":"a4bb1a34-471b-4555-af24-fb6959389923","acronym":"OUTREACH2","url":"https://clinicaltrials.gov/study/NCT04710641","created_at":"2021-01-19T20:52:22.729Z","updated_at":"2024-07-02T16:35:28.099Z","phase":"Phase 2","brief_title":"Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone","source_id_and_acronym":"NCT04710641 - OUTREACH2","lead_sponsor":"Mina Alpha Limited","biomarkers":" CEBPA","pipe":"","alterations":" ","tags":["CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • MTL-CEBPA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-11-27"},{"id":"ec691ea0-9e7c-4022-8073-c784470d60c2","acronym":"OUTREACH","url":"https://clinicaltrials.gov/study/NCT02716012","created_at":"2021-01-18T13:16:58.176Z","updated_at":"2024-07-02T16:35:28.063Z","phase":"Phase 1","brief_title":"First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer","source_id_and_acronym":"NCT02716012 - OUTREACH","lead_sponsor":"Mina Alpha Limited","biomarkers":" CEBPA","pipe":"","alterations":" ","tags":["CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • MTL-CEBPA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-27"},{"id":"1ad88123-0252-4396-b11e-03e4cec2a03f","acronym":"","url":"https://clinicaltrials.gov/study/NCT00634634","created_at":"2021-01-18T02:21:42.930Z","updated_at":"2025-02-25T15:49:14.321Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer","source_id_and_acronym":"NCT00634634","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" ER • PGR","pipe":" | ","alterations":" ER positive","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • letrozole"],"overall_status":"Completed","enrollment":" Enrollment 52","initiation":"Initiation: 08/11/2008","start_date":" 08/11/2008","primary_txt":" Primary completion: 04/20/2019","primary_completion_date":" 04/20/2019","study_txt":" Completion: 04/28/2023","study_completion_date":" 04/28/2023","last_update_posted":"2023-11-09"},{"id":"e19ac03a-6d69-47b6-b1d1-abbab9f5f9bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06073730","created_at":"2023-10-10T15:12:26.222Z","updated_at":"2024-07-02T16:35:34.188Z","phase":"Phase 3","brief_title":"Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT06073730","lead_sponsor":"The Second Affiliated Hospital of Kunming Medical University","biomarkers":" RUNX1","pipe":"","alterations":" ","tags":["RUNX1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • sorafenib • azacitidine • decitabine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-10-09"},{"id":"9a6cb932-a743-45c0-92c6-ba2f1867ff26","acronym":"","url":"https://clinicaltrials.gov/study/NCT04723004","created_at":"2021-01-25T15:53:29.848Z","updated_at":"2024-07-02T16:35:40.247Z","phase":"Phase 3","brief_title":"Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC","source_id_and_acronym":"NCT04723004","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • sorafenib • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 326","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-08-11"},{"id":"2d6867ac-90da-4cfa-8f02-85cdea6ec075","acronym":"","url":"https://clinicaltrials.gov/study/NCT00516828","created_at":"2021-01-18T01:51:57.861Z","updated_at":"2025-02-25T17:15:17.128Z","phase":"Phase 1/2","brief_title":"Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT00516828","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" FLT3","pipe":"","alterations":" ","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • cytarabine"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/27/2007","start_date":" 11/27/2007","primary_txt":" Primary completion: 03/18/2010","primary_completion_date":" 03/18/2010","study_txt":" Completion: 01/10/2013","study_completion_date":" 01/10/2013","last_update_posted":"2023-08-04"},{"id":"ea259fb5-3f93-4045-aa2d-a83218c93202","acronym":"","url":"https://clinicaltrials.gov/study/NCT01141309","created_at":"2021-01-18T04:32:19.305Z","updated_at":"2024-07-02T16:35:42.533Z","phase":"Phase 2","brief_title":"Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer","source_id_and_acronym":"NCT01141309","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTEN • TG","pipe":" | ","alterations":" PTEN mutation • MTOR mutation","tags":["PTEN • TG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • MTOR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • everolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 06/01/2010","start_date":" 06/01/2010","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2023-07-19"},{"id":"9ae7ce18-a20f-474a-a6f4-17a8162e7b3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01817751","created_at":"2021-03-25T16:50:49.924Z","updated_at":"2024-07-02T16:35:51.245Z","phase":"Phase 2","brief_title":"Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT01817751","lead_sponsor":"Virginia Commonwealth University","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA expression","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • sildenafil"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/11/2013","start_date":" 04/11/2013","primary_txt":" Primary completion: 08/27/2020","primary_completion_date":" 08/27/2020","study_txt":" Completion: 10/30/2027","study_completion_date":" 10/30/2027","last_update_posted":"2023-04-06"}]